LAX.SH
AARTI PHARMALABS LIMITED·PHARMACEUTICALS 66.37CDMO 77.10·Pharmaceuticals & Biotechnology Companies
Price
828.8
-1.72%52W Range
Market Cap
₹7,515.54 Cr
Traded: ₹34.45 Cr (0.46%) 0.0x
Free Float: ₹3,054.32 Cr (1.13% of FF traded)
Volume · 60D trend
4.15 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | +13.0% | +12.0% | -- | -- | Decelerating |
| Return | -- | -- | +27.0% | -19.0% | -- | Decelerating |
| Profit | -- | -- | -3.0% | -- | -19.0% | Decelerating |
| Sales | -- | -- | -2.0% | -- | +1.0% | Accelerating |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 536 | 583 | 432 | 418 | 386 | 564 | 538 | 458 | 555 | 506 | 449 | 440 | 458 | 485 | 472 | 531 |
| Expenses | 400 | 470 | 330 | 344 | 293 | 418 | 409 | 364 | 459 | 388 | 353 | 352 | 373 | 405 | 385 | 441 |
| Operating Profit | 136 | 113 | 102 | 74 | 93 | 146 | 129 | 94 | 96 | 118 | 96 | 88 | 85 | 80 | 86 | 90 |
| Other Income | 8 | 14 | 2 | 0 | 2 | -2 | 5 | 4 | 2 | 2 | 1 | 1 | 0 | 1 | 0 | 1 |
| Interest | 13 | 17 | 13 | 11 | 7 | 7 | 10 | 6 | 5 | 5 | 4 | 4 | 4 | 6 | 5 | 6 |
| Depreciation | 30 | 28 | 29 | 25 | 23 | 23 | 23 | 21 | 20 | 19 | 19 | 18 | 17 | 16 | 16 | 17 |
| Profit Before Tax | 101 | 82 | 63 | 39 | 65 | 115 | 101 | 72 | 74 | 96 | 74 | 67 | 64 | 59 | 65 | 69 |
| Tax % | 25.0% | 25.0% | 24.0% | 28.0% | 24.0% | 23.0% | 26.0% | 24.0% | 25.0% | 32.0% | 29.0% | 23.0% | 26.0% | 27.0% | 27.0% | 26.0% |
| Net Profit | 76 | 61 | 48 | 28 | 50 | 88 | 74 | 55 | 55 | 65 | 53 | 52 | 47 | 43 | 48 | 51 |
| Exceptional Items | -- | 0 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -- |
| EPS (Rs) | 8.4 | 6.7 | 5.3 | 3.1 | 5.5 | 9.8 | 8.2 | 6.0 | 6.1 | 7.2 | 5.8 | 5.7 | 5.2 | 4.7 | 5.3 | -- |
| Sales Growth (YoY) | 38.9% | 3.4% | -19.7% | -8.7% | -30.4% | 11.5% | 19.8% | 4.1% | 21.2% | 4.3% | -4.9% | -17.1% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -8.1% | 35.0% | 3.4% | 8.3% | -31.6% | 4.8% | 17.5% | -17.5% | 9.7% | 12.7% | 2.0% | -3.9% | -5.6% | 2.8% | -11.1% | -- |
| OP Growth (YoY) | 46.2% | -22.6% | -20.9% | -21.3% | -3.1% | 23.7% | 34.4% | 6.8% | 12.9% | 47.5% | 11.6% | -2.2% | -- | -- | -- | -- |
| OP Growth (QoQ) | 20.4% | 10.8% | 37.8% | -20.4% | -36.3% | 13.2% | 37.2% | -2.1% | -18.6% | 22.9% | 9.1% | 3.5% | 6.3% | -7.0% | -4.4% | -- |
| Profit Growth (YoY) | -- | -31.0% | -32.0% | -49.0% | -11.0% | 35.0% | 40.0% | 5.0% | 18.0% | 52.0% | 11.0% | 1.0% | -9.0% | -12.0% | -- | -- |
| EPS Growth (YoY) | 53.9% | -30.9% | -35.2% | -48.9% | -10.8% | 35.4% | 40.2% | 5.4% | 17.7% | 52.2% | 10.7% | -- | -- | -- | -- | -- |
| EPS Growth (QoQ) | 24.6% | 27.4% | 71.8% | -43.6% | -44.0% | 19.5% | 35.3% | -1.5% | -15.0% | 23.7% | 1.8% | 10.0% | 9.9% | -10.1% | -- | -- |
| OP Margin | 25.4% | 19.4% | 23.6% | 17.7% | 24.1% | 25.9% | 24.0% | 20.5% | 17.3% | 23.3% | 21.4% | 20.0% | 18.6% | 16.5% | 18.2% | 16.9% |
| Net Margin | 14.2% | 10.5% | 11.1% | 6.7% | 12.9% | 15.6% | 13.8% | 12.0% | 9.9% | 12.8% | 11.8% | 11.8% | 10.3% | 8.9% | 10.2% | 9.6% |
| Material Cost % | -- | 48.6% | 39.9% | 50.1% | 43.9% | 49.4% | 48.6% | 50.0% | 58.8% | 50.0% | 54.5% | 57.4% | 59.1% | 60.8% | 57.4% | 63.0% |
| Employee Cost % | -- | 7.7% | 10.0% | 10.4% | 10.7% | 7.7% | 7.7% | 8.2% | 7.1% | 7.4% | 8.1% | 7.2% | 7.3% | 6.8% | 7.4% | 6.0% |
| P/S | 3.82 | 3.42 | 3.69 | 3.44 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 35.25 | 33.34 | 31.06 | 27.36 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 3.54 | 2.93 | 3.25 | 3.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50This is to inform you that the Earnings Conference Call for investors and analysts has been scheduled for Thursday, October 28, 2026, at 3:30 p.m. (IST) to discuss the Company''s Q2-FY27 ....
Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve Unaudited Standalone And Consolidated ....
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, for the quarter ended September 30, 2026.
Please find enclosed
Please find enclosed
Closure of Trading Window
Please find enclosed
Scrutinizers Report and Voting Result of 7th Annual General Meeting
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Gloire Trusteeship Services Pvt Ltd & Others
Investor Presentation made at the 7th Annual General Meeting
Proceedings of the 7th Annual General Meeting
Please find enclosed
Please find enclosed
Please find enclosed
Please find enclosed, Annual Report for FY 2025-26
Please find enclosed BRSR for FY 2025-26
Please find enclosed
Please find enclosed
Q1 FY 27 Earnings Call Transcript
Disclosure as enclosed
Audio Recording of Conference Call for Investor and Analysts
Q1 FY 2027 Investor Presentation
Newspaper Publication on Financial Results
Approval of Unaudited Financial Results (Standalone and Consolidated) for the Quarter Ended June 30, 2026
Disclosure as enclosed
Disclosure as enclosed
As enclosed
Outcome of Board Meeting held on August 07, 2026.
Please find enclosed
Please find enclosed
Please find enclosed
Intimation of Closure of Trading Window
Transcript of Q4 FY 26 Earnings Conference Call.
Newspaper Publication of Financial Results
Audio Recording of Conference Call for Investor and Analysts
The Outcome was intimated within the prescribed timelines under various heads however the same was inadvertently missed under Results Tab, therefore uploading the same.
Please find attached Investor Presentation
Annual Secretarial Compliance Report for the Financial Year 2025-26
Designated SMPs as enclosed
As Enclosed
Recommendation of final dividend, subject to the approval of the shareholders at the ensuing Annual General Meeting.
Please find attached our intimation on captioned subject.
Outcome of the Board meeting held on 25th May, 2026
This is to inform you that the Earnings Conference Call for Investors and Analysts has been scheduled on Tuesday, May 26, 2026 at 4:00 P.M. (IST) to discuss the Company''s Q4 FY26 Financial Results.
Intimation of Conference Call
The Board Meeting to be held on 18/05/2026 has been revised to 25/05/2026 The meeting of the Board of Directors of the Company has been rescheduled to May 25, 2026
Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2026 ,inter alia, to consider and approve The Audited Financial Results ....
Please find our intimation on captioned subject
Newspaper Advertisement for the Second 100-Day Campaign - "Saksham Niveshak"
Please find our intimation on captioned subject.
Credit Ratings
5Concalls
15Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Sep 2025
30 Sept 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Sep 2023
30 Sept 2023Aug 2023
31 Aug 2023Jun 2023
30 Jun 2023Held by ETFs
2 ETFs hold aartipharm · sorted by weight
Held by Mutual Funds
9 schemes hold aartipharm · sorted by weight